KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Research & Development (2016 - 2025)

BeOne Medicines (ONC) has disclosed Research & Development for 11 consecutive years, with $615.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 13.54% to $615.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 billion, a 9.86% increase, with the full-year FY2025 number at $2.1 billion, up 9.86% from a year prior.
  • Research & Development was $615.4 million for Q4 2025 at BeOne Medicines, up from $523.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $615.4 million in Q4 2025 to a low of -$958.0 million in Q4 2023.
  • A 5-year average of $276.8 million and a median of $424.6 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 256.46% in 2021, then surged 156.57% in 2024.
  • BeOne Medicines' Research & Development stood at -$556.3 million in 2021, then decreased by 0.19% to -$557.3 million in 2022, then tumbled by 71.9% to -$958.0 million in 2023, then surged by 156.57% to $542.0 million in 2024, then grew by 13.54% to $615.4 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Research & Development are $615.4 million (Q4 2025), $523.7 million (Q3 2025), and $524.9 million (Q2 2025).